Performance of Amino Acid Positons Emission Tomography in Brain Metastases

Differentiating radiation necrosis from tumor progression in patients with brain metastases treated with radiotherapy is a major challenge in post-treatment management, as the therapeutic and prognostic implications differ substantially depending on whether the lesion represents radiation necrosis (surveillance, anti-angiogenic therapy) or tumor progression (re-initiation of local or systemic treatment).

In addition to brain MRI, amino acid PET imaging, including both static and dynamic acquisitions, is a key diagnostic tool for this purpose.

However, the added value of dynamic acquisitions remains uncertain, and the available evidence is limited to small patient series.

Inclusion criteria

• Patients who received a PET amino acid for differentiating radiation necrosis from progression of irradiated brain metastases,

Exclusion criteria

• Patients who refused the using of their data